GSK .........filling its pipeline

GSK over the past one year has made several mega deals for Cancer treatment, Yesterday again it signed a new collaboration, in which it will utilize technology from Chroma therapeutics from UK. In this deal GSK will pay chroma $1 billion in fees, milestones and options. The money will be used to advance Chroma's CHR-2797 into a late-stage cancer study and to move further another compound CHR-2845 toward clinical proof-of-concept.

It is notable that with these series of M&A and collaboration, GSK is filling its pipeline for cancer treatment for the coming decades and will thus become one of the prominent player for cancer therapeutics domain.